Cargando…
Surgery in rheumatic and musculoskeletal disease /
"Surgery in Systemic Autoimmune Disease, Volume 15, describes the state-of-the-art of the use of surgery in treating the most common systemic autoimmune diseases (SADS). The volume consists of an introductory chapter concerning the impact of surgery on SADs, follow by eight chapters describing...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands :
Elsevier,
[2018]
|
| Colección: | Handbook of systemic autoimmune diseases ;
v. 15. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Surgery in Rheumatic and Musculoskeletal Disease; Handbook of Systemic Autoimmune Diseases; Surgery in Rheumatic and Musculoskeletal Disease; Copyright; Dedication; Contents; List of Contributors; Preface; 1
- The Spectrum of Rheumatic Diseases; 1. INTRODUCTION; 2. SYSTEMIC AUTOIMMUNE DISEASES; 2.1 Systemic Lupus Erythematosus; 2.2 Rheumatoid Arthritis; 2.3 Systemic Sclerosis; 2.4 Idiopathic Inflammatory Myopathies; 2.5 Antiphospholipid Syndrome; 3. AUTOINFLAMMATORY DISEASES; 4. METABOLIC DISEASES; 4.1 Osteoporosis; 4.2 Crystal Deposition Disease
- 4.2.1 Calcium Pyrophosphate Disease (CPPD)4.3 Gout; 5. DEGENERATIVE DISEASES; 5.1 Osteoarthritis; 6. CONCLUSIONS; KEYPOINTS; REFERENCES; 2
- Comorbidities in Patients With Rheumatic Disease; 1. INTRODUCTION; 1.1 The Concepts of Comorbidity and Multimorbidity; 1.2 Prevalence of Multimorbidity in Rheumatic Conditions; 2. ASSESSMENT OF COMORBID CONDITIONS; 3. IMPACT OF COMORBIDITIES ON IMPORTANT OUTCOMES; 3.1 Mortality; 3.2 Health Economic Implications; 3.3 Disease-Related Outcomes; 3.4 Outcomes Related to Surgery; 4. DISTINCT COMORBID CONDITIONS; 4.1 Cardiovascular Disease
- 4.2 Pulmonary Disease4.3 Malignancies; 4.4 Gastrointestinal Disease; 4.5 Infections; 4.6 Osteoporosis; 4.7 Depression; 5. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; REFERENCES; 3
- Drugs Used in Rheumatic Disease; 1. INTRODUCTION; 2. NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 3. GLUCOCORTICOIDS; 4. IMMUNOSUPPRESSANTS/IMMUNOMODULATORS AND DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 4.1 Nonbiological Agents; 4.1.1 Methotrexate; 4.1.2 Leflunomide; 4.1.3 Sulfasalazine; 4.1.4 Antimalarials; 4.1.5 Cyclophosphamide; 4.1.6 Azatihioprine; 4.1.7 Mycophenolate Mofetil
- 4.1.8 Cyclosporine and Tacrolimus4.1.9 Apremilast; 4.1.10 Tofacitinib; 4.2 Biologicals; 4.2.1 Tumor Necrosis Factor-Alpha Inhibitors; 4.2.2 Tocilizumab; 4.2.3 Anakinra, Canakinumab, and Rilonacept; 4.2.4 Rituximab; 4.2.5 Abatacept; 4.2.6 Secukinumab; 4.2.7 Ustekinumab; 4.2.8 Belimumab; 5. COLCHICINE; 6. URATE-LOWERING AGENTS; 7. CONCLUSION; KEY POINTS; LIST OF ACRONYMS AND ABBREVIATIONS; DEDICATION; REFERENCES; 4
- Essential and Optional Drugs for Rheumatic Diseases; 1. RHEUMATOID ARTHRITIS AND SPONDYLARTHRITIDES; 2. GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA; 3. VASCULITIDES
- 4. CONNECTIVE TISSUE DISEASES5. BASIC LABORATORY ASSESSMENT; 6. GLUCOCORTICOIDS; 7. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; 8. DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 9. ANTIMALARIALS; 10. CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 10.1 Methotrexate; 10.2 Sulfasalazine; 10.3 Leflunomide; 11. BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS; 11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab); 11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab); 11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)